Lignan extracted from radix ephedrae as well as preparation method and application of lignan

By extracting monoepoxy lignans and benzofuran lignans from ephedra roots, the problem of lack of effective natural products in the treatment of depression is solved, the medicinal value of ephedra roots is achieved, and the effective anti-epidemic Depressive active compounds have significant clinical application value.

CN118930528AActive Publication Date: 2024-11-12HENAN UNIV OF CHINESE MEDICINE
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410943043.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-11-12
Estimated Expiration
2044-07-15

AI Technical Summary

Technical Problem

The prior art lacks effective natural products in the treatment of depression, and the chemical research on ephedra roots is limited, which limits its development and utilization.

Method used

Ephedra root E of monoepoxy lignans and ephedra root G of benzofuran-type lignans were extracted from ephedra roots, and the water decoction method, ethanol reflux method, petroleum ether extraction, dichloromethane extraction, Ethyl acetate extraction and n-butanol extraction were separated by silica gel column chromatography and HPLC to obtain a compound with antidepressant activity.

Benefits of technology

The prepared lignan compound has significant antidepressant activity, can improve the damage of PC-12 cells induced by corticosterone, provides the application of new drugs for the treatment of depression, opens up the medicinal value of ephedra root, and has great economic and Social benefits.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930528A_ABST
    Figure CN118930528A_ABST
Patent Text Reader

Abstract

The preparation method comprises the following steps: performing reflux extraction and concentration on the ephedra sinica stapf root which is decocted and extracted by adding water by using ethanol to obtain an extract, dispersing and dissolving by using water, and extracting by using petroleum ether, dichloromethane, ethyl acetate and n-butyl alcohol to obtain a corresponding part; carrying out silica gel column chromatography separation on the dichloromethane part, carrying out gradient elution and chromatographic separation by using petroleum ether-ethyl acetate and dichloromethane-methanol, then carrying out gradient elution and chromatographic separation by using petroleum ether-ethyl acetate and dichloromethane, collecting a retention time fraction, concentrating and drying to obtain ephedra root phenol E; the ephedra root phenol G is obtained through ethyl acetate part chromatographic separation, gradient elution, vacuum concentration, spray detection, same fraction merging, chromatographic column loading, retention time fraction collection, concentration and drying, the method is easy to operate, the product purity is high, the ephedra root phenol G has the anti-depression activity and is effectively used for preparing the medicine for treating depression, the medicinal value of ephedra roots is developed, and the economic and social benefits are huge.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of traditional Chinese medicine, in particular to monoepoxy lignans and benzofuran lignans for depression, a lignan extracted from ephedra root, and a preparation method and application thereof. Background Art

[0002] Depression is a mental illness characterized by emotional dysfunction, slow thinking, decreased willpower, cognitive impairment and social dysfunction. According to a WHO survey, depression is widespread worldwide. In my country alone, the number of people suffering from depression accounts for 4.2% of the total population. The survey shows that the proportion of female depression patients in China is higher than that of male patients, and the number of unemployed people is higher than that of employed people. The main incidence group is adults. Studies have found that the continuous increase in the level of corticosterone in plasma and cerebrospinal fluid may play an important role in the occurrence of depression. Therefore, the use of corticosterone-induced PC-12 cell injury model to screen the antidepressant activity of compounds and to find natural products with potential antidepressant activity is an urgent technical problem for pharmaceutical researchers.

[0003] Ephedra root, also known as bitter toon vegetable, is the dried root and rhizome of Ephedra sinica Stapf. or Ephedra intermedia Schrenket CAMey. of the Ephedraceae Dumortier genus Ephedra, which is included in the Chinese Pharmacopoeia. The modern pharmacological activities of Ephedra root are mainly manifested in antihypertensive, anti-oxidant, anti-inflammatory and anti-tumor effects. Its main chemical components are alkaloids, flavonoids and lignans. In my country, Ephedra sinica is mainly produced in Hebei, Inner Mongolia, Sichuan, Shanxi and other places. Due to the lack of research on the chemistry of Ephedra root, its activity research is even weaker, which seriously curbs the development and utilization of Ephedra root. Therefore, ephedra root was used as the research object, and its chemical components were systematically extracted, separated and structurally identified. New lignan compounds were isolated from it, and the activity of the compounds was screened using the corticosterone-induced PC-12 cell damage model. The results showed that the compounds could significantly improve corticosterone-induced PC-12 cell damage and had potential antidepressant activity, and could be used in the preparation of drugs for the treatment of depression. However, there has been no public report on this so far. Summary of the invention

[0004] In view of the above situation, in order to overcome the shortcomings of the prior art, the purpose of the present invention is to provide a lignan extracted from the root of ephedra and its preparation method and application, which can effectively solve the problem of medication for the treatment of depression.

[0005] The technical solution provided by the present invention is: a lignan extracted from the root of ephedra, wherein the lignan is ephedra root phenol E of the monoepoxy lignan class and ephedra root phenol G of the benzofuran type lignan, and the molecular formulas thereof are: ephedra root phenol E is C 24 H 28 O6; Ephedrine G is C 19 H 22 O8; molecular structures are:

[0006]

[0007] The preparation method is as follows: take the dried root and rhizome of ephedra sinica, add water 15 times of the weight volume, extract twice by water decoction method, each time for 2 hours, the weight volume refers to the solid in kg and the liquid in L, extract the root of ephedra sinica after water decoction and extraction twice by heating and reflux device with 95% volume concentration ethanol (hereinafter referred to as ethanol), add 4L ethanol to 1kg of ephedra sinica root each time, heat and reflux for 2h, concentrate the extract under reduced pressure to obtain extract, disperse and dissolve the extract in water, extract with petroleum ether 5 times in sequence, each time the amount is 0.7 times of the weight volume of the extract, extract with dichloromethane 10 times, each time the amount is 1 times of the weight volume of the extract, extract with ethyl acetate 12 times, each time the amount is 1 times of the weight volume of the extract, extract with n-butanol 6 times, each time the amount is 0.6 times of the weight volume of the extract, recover the solvent, obtain petroleum ether part, dichloromethane part The fraction M3-1 was separated by 200-300 mesh silica gel column chromatography, and then the fraction M3-2 was separated by 30:1, 20:1, 10:1, 5:1, 10:1, 5:1, and dichloromethane-methanol gradient elution to obtain the corresponding fractions M3-1, M3-2, M3-3, M3-4, and M3-5. The fraction M3-3 was separated by semi-preparative HPLC, and the upper specification model was: 250×10mm, particle size 5μm, pore size 12nm 5C 18 -MS-Ⅱ chromatographic column, the mobile phase is a mixture of 0.45% triethylamine aqueous solution and methanol, the volume ratio of aqueous solution to methanol is 15:84, the flow rate is 3ml / min, and the retention time t R = The fraction from 23 to 25 min was concentrated and dried to obtain ephedrine root phenol E;

[0008] The ethyl acetate fraction was separated by 100-200 mesh silica gel column chromatography to obtain the sample silica gel, which was gradient eluted with dichloromethane-methanol in a volume ratio of 50:1, 30:1, 20:1, 10:1, 5:1, and 3:1 to obtain the corresponding fractions E1, E2, E3-E9. Fraction E9 was separated by 200-300 mesh silica gel column chromatography and gradient eluted with petroleum ether-ethyl acetate in a volume ratio of 20:1, 10:1, 5:1, 5:1, 1:1, and 2:3 to obtain the corresponding fractions E9-1, E9-2-E9-5. Fraction E9-2 was concentrated under reduced pressure and purified by Toyopearl HW-40C gel column chromatography, eluted with 50% and 70% methanol by volume, the amount used for each elution position was 10 times the column volume, anisaldehyde-concentrated sulfuric acid spray detection was used, and detection was performed every 5 ml. The same fractions were combined to obtain components E9-2-1, E9-2-2, E9-2-3, and E-9-2-4. Component E-9-2-3 was concentrated under reduced pressure and eluted with Sephadex LH-20 gel column chromatography with 70% methanol by volume. Anisaldehyde-concentrated sulfuric acid spray detection was used, and detection was performed every 3 ml. The same fractions were combined to obtain components E9-2-3-1, E9-2-3-2, and E-9-2-3-3. Component E-9-2-3-2 was separated by semi-preparative HPLC. The upper specification model is: 250×10mm, particle size 5μm, pore size 12nm 5C 18 -MS-Ⅱ chromatographic column, mobile phase is methanol: water = 15:85 by volume, flow rate is 3ml / min, collection retention time t R = The fraction from 26 to 28 min was concentrated to dryness to obtain compound ephedrine G.

[0009] The lignans prepared by the method are ephedrine E of the monoepoxy lignan class and ephedrine G of the benzofuran-type lignan class, which have antidepressant activity and can be effectively used in preparing drugs for treating depression, thereby realizing the application of the method in preparing drugs for treating depression.

[0010] The invention has abundant raw materials, is easy to operate in the preparation method, has good product quality, good extraction effect and high purity, and the obtained compound has antidepressant activity, can be used in the preparation of drugs for treating depression, expands the medicinal value of ephedra root, and has huge economic and social benefits. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 The ephedra root phenol E of the present invention 1 H-NMR spectrum (in 500MHz,CDCl3) chart.

[0012] Figure 2 The ephedra root phenol E of the present invention 13 C-NMR spectrum (in 125MHz,CDCl3) chart.

[0013] Figure 3 The figure is the HR-ESI-MS spectrum (in MeOH) of ephedra root phenol E of the present invention.

[0014] Figure 4 The IR spectrum (in MeOH) of ephedra root phenol E of the present invention is shown in FIG.

[0015] Figure 5 The UV spectrum (in MeOH) of ephedra root phenol E of the present invention.

[0016] Figure 6 For the ephedrine G of the present invention 1 H-NMR spectrum (in 500MHz, CD3OD) chart.

[0017] Figure 7 For the ephedrine G of the present invention 13 C-NMR spectrum (in 125MHz, CD3OD) chart.

[0018] Figure 8 The figure is the HR-ESI-MS spectrum (in MeOH) of ephedra root phenol G of the present invention.

[0019] Fig. 9 The IR spectrum (in MeOH) of ephedra root phenol G of the present invention.

[0020] Fig.10 The UV spectrum (in MeOH) of ephedra root phenol G of the present invention.

[0021] Fig.11 It is a molecular structural formula diagram of ephedrine root phenol E and ephedrine root phenol G of the present invention.

[0022] Fig.12 1H-1H COSY correlation and HMBC correlation diagram of ephedra root phenol E and G.

[0023] Fig.13 The effect of ephedra root phenol E (1) and G (2) on the cell survival rate in the corticosterone-induced PC-12 cell injury model ( n=4. ## P<0.01vs CORT; *P<0.05, **P<0.01vs CORT). DETAILED DESCRIPTION

[0024] The specific implementation modes of the present invention are described in detail below in combination with embodiments and specific situations.

[0025] The present invention can be specifically implemented by the following embodiments:

[0026] The present invention discloses a lignan extracted from the root of Ephedra sinica. The lignan is Ephedra sinica E of the monoepoxy lignan class and Ephedra sinica G of the benzofuran type lignan class. The molecular formulas thereof are: Ephedra sinica E is C 24 H 28 O6; Ephedrine G is C 19 H 22 O8; molecular structures are:

[0027]

[0028] The preparation method thereof is:

[0029] Take 40kg of dried roots and rhizomes of Ephedra sinica, extract them twice with 600L water by water decoction method, each time for 2 hours, extract the roots of Ephedra sinica after water decoction and extraction with 95% ethanol using a heating reflux device twice, add 4L ethanol per kg of Ephedra sinica root each time, heat and reflux for 2h, concentrate the extract under reduced pressure to obtain 10.0kg of extract, disperse and dissolve in water, extract with petroleum ether 5 times, 7L each time, extract with dichloromethane 10 times, 10L each time, extract with ethyl acetate 12 times, 10L each time, extract with n-butanol 6 times, 6L each time, recover the solvent to obtain 211.6g of petroleum ether part, 245.1g of dichloromethane part, 335.5g of ethyl acetate part, 62.5g of n-butanol part, and dissolve the dichloromethane part by 1 2000 g of silica gel was separated by 200-200 mesh silica gel column chromatography to obtain 270 g of sample silica gel. Gradient elution was performed using petroleum ether-ethyl acetate in a volume ratio of 10:1, 5:1, 3:1, 1:1 and dichloromethane-methanol 20:1 to obtain the corresponding fractions M1, M2, M3-M5. Fraction M3 was separated by 200-300 mesh silica gel column chromatography and gradient elution was performed using petroleum ether-ethyl acetate in a volume ratio of 30:1, 20:1, 10:1, 5:1 and dichloromethane to obtain the corresponding fractions M3-1, M3-2, M3-3-M3-5. Fraction M3-3 was separated by semi-preparative HPLC. The upper specification model is: 250×10 mm, particle size 5 μm, pore size 12 nm 5C 18 -MS-Ⅱ chromatographic column, the mobile phase is a mixture of 0.45% triethylamine aqueous solution and methanol, the volume ratio of aqueous solution to methanol is 15:84, the flow rate is 3ml / min, and the retention time t R = The fraction from 23 to 25 min was concentrated to dryness to obtain ephedrine E (6.12 mg);

[0030] 335.5 g of the ethyl acetate fraction was separated by 100-200 mesh silica gel column chromatography with 6000 g of silica gel to obtain 500 g of sample silica gel, which was gradient eluted with dichloromethane-methanol in a volume ratio of 50:1, 30:1, 20:1, 10:1, 5:1, and 3:1 to obtain the corresponding fractions E1-E9. Fraction E9 was separated by 200-300 mesh silica gel column chromatography and gradient eluted with petroleum ether-ethyl acetate in a volume ratio of 20:1, 10:1, 5:1, 5:1, 1:1, and 2:3 to obtain the corresponding fractions E9-1, E9-2-E9-5. Fraction E9-2 was concentrated under reduced pressure and purified by Toyopearl HW-40C gel column chromatography, eluted with 50% and 70% methanol by volume, the amount used for each elution position was 10 times the column volume, anisaldehyde-concentrated sulfuric acid spray detection was used, and detection was performed every 5 ml. The same fractions were combined to obtain components E9-2-1, E9-2-2, E9-2-13, and E-9-2-4. Component E-9-2-3 was concentrated to 15 mL under reduced pressure, and Sephadex LH-20 gel column chromatography was used, eluted with 70% methanol, anisaldehyde-concentrated sulfuric acid spray detection was used, and detection was performed every 3 ml. The same fractions were combined to obtain components E9-2-3-1, E9-2-3-2, and E-9-2-3-3. Component E-9-2-3-2 was separated by semi-preparative HPLC, and the upper specification model was: 250×10mm, particle size 5μm, pore size 12nm 5C 18 -MS-Ⅱ chromatographic column, mobile phase is methanol: water = 15:85 by volume, flow rate is 3ml / min, collection retention time t R = The fraction from 26 to 28 min was concentrated to dryness to obtain compound ephedrine G (3.86 mg).

[0031] According to the composition given in the above embodiment, any amount of Chinese medicine can be prepared as needed. The given embodiment is only used to illustrate the specific implementation mode of the present invention, rather than to limit the protection scope of the present invention. The technical core protected by the present invention is the Chinese medicine composition, and the Chinese medicine composition can be prepared into any required amount of ephedrine E and ephedrine G according to actual needs.

[0032] The invention has abundant raw materials, the preparation method is easy to operate, the yield is high, the quality is good, the purity is high, the prepared ephedra root phenol E and ephedra root phenol G have antidepressant activity, can be effectively used to treat depression, and can be used in the preparation of drugs for treating depression. After experiments, very good beneficial technical effects have been achieved. The relevant information is as follows:

[0033] 1. Experimental instruments and test drugs.

[0034] Bruker AVANCEⅢ500 NMR instrument (TMS internal standard) (Bruker) was used for NMR, Nicolet is 10 Microscope Spectrometer (Thermo Scientific, USA) was used for infrared spectroscopy, Bruker maxis HD mass spectrometer was used for high-resolution mass spectrometry, Shimadzu UV-2401PC apparatus was used for UV spectroscopy, Waters Alliance series 2695 HPLC system was used for HPLC, equipped with 2998 diode array detector, Empower3 chromatography data workstation, LC50 high pressure preparative liquid chromatograph, UV200 UV detector [Sepures (Beijing) Technology Co., Ltd.], YMC-Pack ODS-A chromatographic column (250×10mm.DS-5mm,12mm) (YMC Co., Ltd.), the rest include N-1100 rotary evaporator (Shanghai Ailang Instrument Co., Ltd.), A-1000S water flow vacuum pump (Shanghai Ailang Instrument Co., Ltd.), N-1111 chilled water circulation device (Shanghai Ailang Instrument Co., Ltd.), FDU-2110 freeze dryer (Shanghai Ailang Instrument Co., Ltd.), DFZ-60508 vacuum drying oven (Shanghai Yiheng Scientific Instrument Co., Ltd.), AB204-N one-ten-thousandth precision analytical balance (METTLER TOLEDO), iMARK microplate reader (BIO-RAD, USA), carbon dioxide incubator (Shanghai STIK), and clean bench (Sujing Group).

[0035] Rat adrenal pheochromocytoma cells PC-12 were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences; corticosterone (Aladdin Biochemical, Shanghai, China, B2302817); fluoxetine (Med Chem Express, USA, 251273); CCK8 (GLPBIO, USA, 43); 5-HT7 antibody (Miyoshi Biotechnology, Wuhan, China, 00058665); Tubulin antibody (GR3398636-5); DAPI stain (ABCAM, USA, GR3445296-5); column chromatography fillers Diaion HP-20 and MCIGel CHP-20P (Mitsubishi Chemical Corporation, Japan); silica gel H (100-200 mesh) used in column chromatography was produced by Qingdao Ocean Chemical Plant, chromatographic reagents were produced by Tianjin Siyou Fine Chemicals Co., Ltd., and analytical reagents were produced by Beijing Chemical Plant and Tianjin Third Chemical Reagent Plant.

[0036] Goat anti-rabbit IgG H&L (Alexa 488) pre-adsorbed secondary antibody (GR3449096-1); goat anti-mouse IgGH&L (Alexa 594) pre-adsorbed secondary antibody (GR3413419-1, ABCAM, USA); RPMI1640 culture medium (2315381, Invitrogen, USA); fetal bovine serum (12A218, ExCell Bio, South America);

[0037] The Ephedra sinica roots selected for this project were purchased from the Bozhou medicinal materials market in May 2021. They were identified by Professor Dong Chengming of the School of Pharmacy as the dried roots and rhizomes of the Ephedraceae plant Ephedra sinica Stapf. The plant specimen (NO.20210517) is preserved in the Traditional Chinese Medicine Chemical Extraction and Separation Laboratory of Henan University of Traditional Chinese Medicine.

[0038] 2. Structural identification.

[0039] The ephedra root phenol E of the present invention is a white amorphous powder (CH2Cl2) with a purity of (98.2%); HR-ESI-MS gives a quasi-molecular ion peak m / z: 435.1795 [M+Na] + (calculated value is 435.1778), the molecular formula is determined to be C 24 H 28 O6; UV(MeOH)λ max (logε):202(2.47), 233(1.63), 386(1.55)nm; IRν max :3404, 2935, 1490, 1443, 1248cm -1 ; 1 HNMR (CDCl3, 500MHz) and 13 C NMR (CDCl3, 125 MHz) data are shown in Table 1;

[0040] Ephedrine G white amorphous powder (CD3OD), (99.1%); HR-ESI-MS quasi-molecular ion peak m / z: 401.1197 [M+Na] +( Calcd.401.1206), the molecular formula is determined to be C 19 H 22 O8; UV(MeOH)λ max (logε):208(2.68), 281(1.40)nm; IRν max :3400, 2938, 1277, 1029cm -1 ; 1 H NMR (CD3OD, 500 MHz) and 13 C NMR (CD3OD, 125MHz) data are shown in Table 1. 1H-1H COSY correlation and HMBC correlation of ephedrine E and G are shown in Fig.12The molecular structures of ephedrine E and ephedrine G are as follows:

[0041]

[0042] Table 1 NMR spectrum data of ephedra root phenol E and G

[0043]

[0044] a Recorded in CDCl3,b Recorded in CD3OD

[0045] 3. Activity detection

[0046] PC-12 cells were placed in a 5% CO2, 37°C constant temperature incubator and cultured in RPMI1640 medium containing 10% fetal bovine serum. Cells in the best growth period were selected and digested with 0.25% trypsin. After digestion was terminated, RPMI1640 medium containing 10% fetal bovine serum was used to prepare the cells at a concentration of 1×10 4 , inoculated on a 96-well plate, 100 μL of cell suspension per well, placed in an incubator, and after the cells adhered, the culture medium was replaced with a serum-free culture medium. After starvation for 24 h, PC-12 cells were divided into 4 groups: normal group NC (control, cultured in RPMI1640 medium), model group CORT (model, corticosterone), positive control group FXT (fluoxetine, 0.4 μmol·L -1 ), drug-treated group (1-2, 2 μmol·L -1 , i.e., ephedra root phenol E and ephedra root phenol G of the present invention). Each group has 6 duplicate wells. After each group is cultured for 24 hours, a new culture medium is replaced, and 10 μL of CCK8 solution is added to each well. After incubation at 37° C. for 1.5 hours, the absorbance OD value is detected at 450 nm by a microplate reader.

[0047] Cell survival rate = (OD value of drug administration group - OD value of blank group) / (OD value of normal control group - OD value of blank group) × 100%.

[0048] The CCK8 method was used to detect the cell survival rate of ephedra root phenol E and ephedra root phenol G in the corticosterone-induced PC-12 cell injury model. The results are shown in Fig.13 As shown in Table 2, compared with the normal control group, the cell viability of the model group was significantly decreased (P<0.05); compared with the model group, ephedra root phenol E and ephedra root phenol G could significantly improve the cell viability (P<0.01) and improve the damage of corticosterone to PC-12 cells, indicating that ephedra root phenol E and ephedra root phenol G have good potential antidepressant activity.

[0049] Table 2 Effects of compounds on cell survival in the corticosterone-induced PC-12 cell injury model

[0050] Group <![CDATA[Dose (μmol·L -1 )]]> Cell survival rate (%) Normal group (NC) 0 100.00±4.66 Model group (CORT) 800 59.83±4.75 Positive control group (FXT) 0.4 76.40±13.17 Treatment group 1 (ephedrine E) 2 130.51±21.45 Treatment group 2 (ephedrine G) 2 129.34±17.03

[0051] It can be clearly seen from the above that the raw materials of the present invention are abundant, the preparation method is easy to operate, the product quality is good, the extraction effect is good, the yield is high, the purity is as high as 98.5%, and the obtained compound has antidepressant activity and can be used in the preparation of drugs for treating depression. It is an innovation in therapeutic drugs and has practical clinical application value. It has opened up new uses for ephedra root and has huge economic and social benefits.

Claims

1. A lignan extracted from the root of Ephedra, wherein the lignan is Ephedra root phenol E of the monoepoxy lignan class and Ephedra root phenol G of the benzofuran type lignan, and the molecular structural formulas are: 。 2. The method for preparing lignans extracted from the root of Ephedra sinica according to claim 1, It is characterized in that Take the dried roots and rhizomes of Ephedra sinica from which impurities have been removed as raw materials, add water 15 times the weight volume of the raw materials, extract twice by water decoction method, each time for 2 hours, the weight volume refers to the solid in kg and the liquid in L, extract the roots of Ephedra sinica after water decoction and extraction twice by using a 95% volume concentration ethanol heating reflux device, each time 1 kg of Ephedra sinica roots are added with 4L ethanol, heated and refluxed for 2 hours, and the extract is concentrated under reduced pressure to obtain 10kg of extract, the extract is dispersed and dissolved in water, and then extracted with petroleum ether 5 times in sequence, each time the amount is 0.7 times the weight volume of the extract, extracted with dichloromethane 10 times, each time the amount is 1 times the weight volume of the extract, extracted with ethyl acetate 12 times, each time the amount is 1 times the weight volume of the extract, extracted with n-butanol 6 times, each time the amount is 0.6 times the weight volume of the first extract, and recover the solvent to obtain petroleum ether. Ether part, dichloromethane part, ethyl acetate part, n-butanol part; the dichloromethane part was separated by 100-200 mesh silica gel column chromatography to obtain the sample silica gel, and the volume ratio of petroleum ether-ethyl acetate: 10:1, 5:1, 3:1, 1:1 and dichloromethane-methanol 20:1 were used for gradient elution to obtain the corresponding fractions M1, M2, M3, M4, M5; the 3:1 fraction M3 was separated by 200-300 mesh silica gel column chromatography, and then the volume ratio of petroleum ether-ethyl acetate: 30:1, 20:1, 10:1, 5:1 and dichloromethane were used for gradient elution to obtain the corresponding fractions M3-1, M3-2, M3-3, M3-4, M3-5; the fraction M3-3 was separated by semi-preparative HPLC, the upper specification model is: 250×10mm, particle size 5μm, pore size 12 nm 5C 18 -MS-Ⅱ chromatographic column, the mobile phase is a mixture of 0.45% triethylamine in water and methanol, the volume ratio of water solution to methanol is 15:84, the flow rate is 3ml / min, and the retention time t R =23-25 ​​min fraction, concentrated and dried to obtain ephedra root phenol E; The ethyl acetate fraction was separated from the silica gel by 100-200 mesh silica gel column chromatography to obtain the sample silica gel, which was gradient eluted with dichloromethane-methanol in a volume ratio of 50:1, 30:1, 20:1, 10:1, 5:1, and 3:1 to obtain the corresponding fractions E1, E2, E3-E9. Fraction E9 was separated from the silica gel column by 200-300 mesh silica gel column chromatography and gradient eluted with petroleum ether-ethyl acetate in a volume ratio of 20:1, 10:1, 5:1, 5:1, 1:1, and 2:3 to obtain the corresponding fractions E9-1, E9-2-E9-5. Fraction E9-2 was concentrated under reduced pressure and eluted with Toyopearl HW-40C gel column chromatography with 50% and 70% methanol in sequence, with the amount used for each elution portion being 10 times the column volume. Anisaldehyde-concentrated sulfuric acid was used for spray detection, and every 5 ml was detected once, and the same fractions were combined to obtain components E9-2-1, E9-2-2, E9-2-3, and E-9-2-4. Component E-9-2-3 was concentrated under reduced pressure and chromatographed on a Sephadex LH-20 gel column, eluted with 70% methanol by volume, and sprayed with anisaldehyde-concentrated sulfuric acid for detection. Every 3 ml was detected once, and the same fractions were combined to obtain components E9-2-3-1, E9-2-3-2, and E-9-2-3-3. Component E-9-2-3-2 was separated by semi-preparative HPLC with specifications of 250×10 mm, particle size 5 μm, pore size 12 nm, and 5C 18 -MS-Ⅱ chromatographic column, mobile phase is methanol: water = 15:85 by volume, flow rate is 3ml / min, collection retention time t R = 26-28 min fraction was concentrated to dryness to obtain compound ephedrine G.

3. The method for preparing lignans extracted from the root of Ephedra according to claim 2, It is characterized in that 40 kg of dried roots and rhizomes of Ephedra sinica with impurities removed were taken as raw materials, and 600 L of water was added for decoction and extraction twice, each time for 2 hours. The roots of Ephedra sinica after decoction and extraction were extracted twice with 95% ethanol using a heating reflux device, and 4 L of ethanol was added to each kg of Ephedra sinica root each time, and the extract was heated and refluxed for 2 hours. The extract was concentrated under reduced pressure to obtain 10.0 kg of extract, which was dispersed and dissolved in water, and extracted with petroleum ether 5 times, 7 L each time, with dichloromethane 10 times, 10 L each time, with ethyl acetate 12 times, 10 L each time, and with n-butanol 6 times, 6 L each time. After recovering the solvent, 211.6 g of petroleum ether fraction, 245.1 g of dichloromethane fraction, 335.5 g of ethyl acetate fraction, and 62.5 g of n-butanol fraction were obtained. The dichloromethane fraction was separated by 100-200 mesh silica gel column chromatography to obtain 2000 g of silica gel, and 270 g of sample silica gel was obtained. The volume ratio of petroleum ether-acetic acid was 50.5%. Ethyl ester: 10:1, 5:1, 3:1, 1:1 and dichloromethane-methanol 20:1 for gradient elution to obtain the corresponding fractions M1, M2, M3~M5. Fraction M3 was separated by 200~300 mesh silica gel column chromatography and gradient eluted with petroleum ether-ethyl acetate: 30:1, 20:1, 10:1, 5:1 and dichloromethane in a volume ratio to obtain the corresponding fractions M3-1, M3-2, M3-3~M3-5. Fraction M3-3 was separated by semi-preparative HPLC with a specification model of 250×10mm, particle size 5μm, pore size 12 nm 5C 18 -MS-Ⅱ chromatographic column, the mobile phase is a mixture of 0.45% triethylamine in water and methanol, the volume ratio of water solution to methanol is 15:84, the flow rate is 3ml / min, and the retention time t R = 23-25 ​​min fraction, concentrated to dryness, to obtain 6.12 mg of ephedrine root phenol E; 335.5 g of the ethyl acetate fraction was separated by 100-200 mesh silica gel column chromatography with 6000 g of silica gel to obtain 500 g of sample silica gel, which was gradient eluted with dichloromethane-methanol in a volume ratio of 50:1, 30:1, 20:1, 10:1, 5:1, and 3:1 to obtain the corresponding fractions E1-E9. Fraction E9 was separated by 200-300 mesh silica gel column chromatography and gradient eluted with petroleum ether-ethyl acetate in a volume ratio of 20:1, 10:1, 5:1, 5:1, 1:1, and 2:3 to obtain the corresponding fractions E9-1, E9-2-E9-5. Fraction E9-2 was concentrated under reduced pressure and eluted with 50% and 70% methanol by volume using Toyopearl HW-40C gel column chromatography, with the amount of each elution portion being 10 times the column volume. Anisaldehyde-concentrated sulfuric acid was used for spray detection, and every 5 ml was detected once, and the same fractions were combined to obtain components E9-2-1, E9-2-2, E9-2-13, and E-9-2-4. Component E-9-2-3 was concentrated to 15 mL under reduced pressure and chromatographed on a Sephadex LH-20 gel column, eluted with 70% methanol, and sprayed with anisaldehyde-concentrated sulfuric acid. The detection was performed once every 3 ml, and the same fractions were combined to obtain components E9-2-3-1, E9-2-3-2, and E-9-2-3-3. Component E-9-2-3-2 was separated by semi-preparative HPLC, and the upper specification model was: 250×10 mm, particle size 5 μm, pore size 12 nm 5C 18 -MS-Ⅱ chromatographic column, mobile phase is methanol: water = 15:85 by volume, flow rate is 3ml / min, collection retention time t R = 26-28 min fraction was concentrated to dryness to obtain 3.86 mg of compound ephedrine G.

4. Use of the lignans ephedrine E and ephedrine G prepared by the method of claim 2 or 3 in the preparation of drugs for treating depression.

Citation Information

Patent Citations

  • Series of lignan compounds, pharmaceutical composition, preparation method and application

    CN113149945A